We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+2.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$833M
AUM Growth
-$400M
Cap. Flow
-$240M
Cap. Flow %
-28.81%
Top 10 Hldgs %
56.65%
Holding
156
New
48
Increased
29
Reduced
27
Closed
47

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25M
2
CELG
Celgene Corp
CELG
+$22.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$21.2M
4
MGNX icon
MacroGenics
MGNX
+$18.8M
5
MNKD icon
MannKind Corp
MNKD
+$17.8M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$144M
2
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$69.5M
3
GILD icon
Gilead Sciences
GILD
+$56.7M
4
RPRX
Repros Therapeutics Inc.
RPRX
+$26.6M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$21.8M

Sector Composition

Rank Sector Weight
1 Healthcare 85.14%
2 Miscellaneous 12.73%
3 Consumer Staples 2.06%
4 Consumer Discretionary 0.05%
5 Industrials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HTWR
26
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$7.98M 0.96%
84,900
+79,900
+1,598% +$6.76M
CHTP
27
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$7.54M 0.91%
1,701,639
-1,716,726
-50% -$5.8M
CTIC
28
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$7.13M 0.86%
371,500
-327,967
-47% -$5.97M
GENT
29
DELISTED
GENTIUM SPA ADS
GENT
$6.85M 0.82%
+120,000
New +$5.33M
CVS icon
30
CVS Health
CVS
$121B
$6.39M 0.77%
89,330
+87,030
+3,784% +$5.59M
ZLTQ
31
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$5.78M 0.69%
305,593
+291,890
+2,130% +$4.17M
TARO
32
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$5.6M 0.67%
+56,602
New +$4.91M
AERI
33
DELISTED
Aerie Pharmaceuticals
AERI
$5.39M 0.65%
+300,000
New +$3.91M
GRCE
34
Grace Therapeutics
GRCE
$46.9M
$5.24M 0.63%
9,145
+8,823
+2,740% +$7.23M
ECYT
35
DELISTED
Endocyte, Inc. Common Stock
ECYT
$5.23M 0.63%
671,300
+252,585
+60% +$2.79M
SNDA icon
36
Sonida Senior Living
SNDA
$1.91B
$5.01M 0.6%
13,917
-27,022
-66% -$9M
INFI
37
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$4.83M 0.58%
350,000
+154,845
+79% +$2.19M
ATHX
38
DELISTED
Athersys, Inc. Common Stock
ATHX
$4.25M 0.51%
68,035
-17,970
-21% -$857K
GILD icon
39
Gilead Sciences
GILD
$181B
$3.76M 0.45%
50,000
-814,070
-94% -$56.7M
TNDM icon
40
Tandem Diabetes Care
TNDM
$1.13B
$3.24M 0.39%
+12,560
New +$2.87M
VSTM icon
41
Verastem
VSTM
$665M
$2.52M 0.3%
18,333
-1,756
-9% -$231K
ISEE
42
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.43M 0.29%
+75,000
New +$2.23M
MGCD
43
DELISTED
MGC Diagnostics Corporation
MGCD
$2.27M 0.27%
179,619
+5,170
+3% +$63.2K
CMRX
44
DELISTED
Chimerix, Inc.
CMRX
$2.26M 0.27%
+150,000
New +$2.39M
RGEN icon
45
PUT
Repligen
RGEN
$9.86B
$2.25M 0.27%
165,000
+96,700
+142% +$1.15M
ZGNX
46
DELISTED
Zogenix, Inc.
ZGNX
$2.24M 0.27%
+81,250
New +$1.82M
FPRX
47
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.23M 0.27%
+132,500
New +$1.65M
ECYT
48
CALL
DELISTED
Endocyte, Inc. Common Stock
ECYT
$2.14M 0.26%
+200,000
New +$2.21M
ECYT
49
PUT
DELISTED
Endocyte, Inc. Common Stock
ECYT
$2.14M 0.26%
200,000
+7,000
+4% +$77.3K
AUXL
50
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$2.07M 0.25%
+100,000
New +$1.89M
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2013 Portfolio in Review

As of Q4 2013, Perceptive Advisors held 156 positions worth $833M, down 32% from $1.23B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Perceptive Advisors withdrew a net $240M in Q4 2013, closing 47 positions and reducing 27 holdings. Its most notable exit was ONYX PHARMACEUTICALS INC, an estimated $69.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 78% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in MacroGenics worth $19.7M.

  • Perceptive Advisors's largest Q4 2013 buy was MacroGenics: 717,705 shares worth $19.7M.
  • Perceptive Advisors added most to Vertex Pharmaceuticals in Q4 2013, an estimated $25M increase.
  • Perceptive Advisors's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $144M.
  • Perceptive Advisors fully exited ONYX PHARMACEUTICALS INC in Q4 2013, selling an estimated $69.5M.
  • Perceptive Advisors's ten largest holdings make up 57% of its $833M portfolio in Q4 2013.
  • Perceptive Advisors opened 48 new positions and closed 47 in Q4 2013.
  • Perceptive Advisors's portfolio value fell 32% quarter-over-quarter to $833M.

Based on Perceptive Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.